Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 3/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.32 |
| ▸ | ACACB | O00763 | 3/20 | 0.32 |
| ▸ | ACACA | Q13085 | 3/20 | 0.32 |
| ▸ | BCHE | P06276 | 2/20 | 0.32 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4129693 | 0.89 | ACHE (0.35) | ACHEHTR2CSLC6A4ACACBACACA | |
| SCHEMBL4124618 | 0.83 | ACHE (0.41) | MEN1KMT2ASMN1; SMN2ACHELMNA | |
| SCHEMBL4124614 | 0.82 | ACHE (0.39) | MEN1KMT2ASMN1; SMN2ACHELMNA | |
| SCHEMBL4126281 | 0.80 | CSF1R (0.42) | ACHE | |
| SCHEMBL4125743 | 0.79 | ACHE (0.39) | MEN1KMT2ASMN1; SMN2ACHELMNA | |
| SCHEMBL13596222 | 0.78 | ACHE (0.38) | MEN1KMT2ASMN1; SMN2ACHELMNA | |
| SCHEMBL4120913 | 0.78 | ACHE (0.39) | MEN1KMT2ASMN1; SMN2ACHELMNA | |
| SCHEMBL4112904 | 0.78 | ACHE (0.39) | MEN1KMT2ASMN1; SMN2ACHELMNA | |
| SCHEMBL4112912 | 0.78 | ACHE (0.39) | MEN1KMT2ASMN1; SMN2ACHELMNA | |
| SCHEMBL4133377 | 0.77 | ACHE (0.37) | MEN1KMT2ASMN1; SMN2ACHELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2017275-A1 | BENZISOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | NR1I2, NR1I3, NR0B1 | MEN1 1361/4885KMT2A 1211/4885SMN1; SMN2 3331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.